Corporate Member Update-Seattle Genetics: Upcoming Virtual Program

Seattle Genetics cordially invites you to an educational program

FRONTLINE ADVANCEMENTS: CLINICAL DATA OVERVIEW OF ECHELON-1
Join us to review data from ECHELON-1, a superiority trial comparing ADCETRIS+AVD to ABVD. This trial introduces a bleomycin-free regimen for adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL).1 We’ll also discuss the latest data from the North American subset analyses. Healthcare professionals including hematologist oncologists, medical oncologists, pharmacists, PAs, NPs, and RNs are encouraged to participate in this valuable dialogue.

For more information, click here.

Register here!